news roundup

Worldwide Clinical Trials Acquires Late Stage Research Practice

Worldwide Clinical Trials, Inc. announced that the company has signed an agreement to acquire the Late Stage research practice of Continuum Clinical, LLC. This acquisition will expand Worldwide's ability to help life sciences industry sponsors establish evidence at each stage of the product life cycle.

Certara Launches Quantitative Systems Pharmacology Consortium on Immuno-oncology

Certara announced the launch of its Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium. This new QSP brings together biopharmaceutical companies to create a simulator that can model clinical populations of cancer patients in order to improve the development of immuno-oncology therapies.

Europe Adds More Voices to Orphan Drug Push

Rare disease interests in Europe add more voices to push for greater backing of research incentives, infrastructure.

PAREXEL Introduces Medical Writing Solutions

PAREXEL International Corporation introduced PAREXEL's Medical Writing Solutions, a new offering that provides several communication services needed throughout each critical stage of the drug development and commercialization process.

Articles

Optimal Strategies for Compliance with EMA Policy 0070 on the External Publication of Clinical Data

With the EU's new General Data Protection Regulation coming into force in May this year, the impetus for life sciences firms to cement their data management strategies has increased.

Millennials and their Impact on Clinical Research

The importance of examining this generation's influence on the clinical trial value chain.

RBM

RBM—An Update of Experiences Among European CRAs

An RBM survey conducted in 2014 was repeated in 2016 in order to find out, how knowledge and practical experience with RBM have changed over that time period.

Ask the editor

Lisa Henderson
Editor in Chief
Lisa.Henderson@ubm.com